Stockreport

Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Vaxcyte, Inc.  (PCVX) 
PDF -- VAX-31 Adult Program Phase 1/2 Study Enrollment Complete; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Completed Succ [Read more]